Nonantimicrobial actions of macrolides : Overview and perspectives for future development

• Published in: Pharmacological Reviews
• Main Authors: Kricker, Jennifer A., Page, Clive P., Gardarsson, Fridrik Runar, Baldursson, Olafur, Guðjónsson, Þórarinn, Parnham, Michael J.
• Other Authors: Faculty of Medicine, Clinical Laboratory Services, Diagnostics and Blood Bank, Landspitali - The National University Hospital of Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2021
• Subjects: Gerlar; COVID-19; Sýklalyf; Macrolides; Pharmacology; Anti-bacterial agents; SARS-CoV-2; Molecular Medicine; Ari; Seltjarnarnes; Iceland
• Online Access: https://hdl.handle.net/20.500.11815/3237; https://doi.org/10.1124/PHARMREV.121.000300

Funding text Address correspondence to: Dr. Jennifer A. Kricker, EpiEndo Pharmaceuticals, Eidistorg 13-15, Innovation House, 170 Seltjarnarnes, Iceland. E-mail: [e-mail] This work was supported by an Accelerator grant from the European Innovation Council [Grant 947081]. C.P.P. receives consultancy fees from EpiEndo Pharmaceuticals. J.A.K. and F.R.G. are full-time employees and M.J.P. and T.G. are part-time employees of EpiEndo Pharmaceuticals. Abstract submitted to 15th World Congress on Inflammation, 5–8 June, 2022, Rome, Italy. Jennifer A. Kricker, Bryndís Valdimarsdóttir, Jon Petur Joelsson, Sævar Ingthorsson, Mike J. Parnham, Snævar Sigurdsson, Ari Jón Arason, Ólafur Baldursson, Fridrik R. Gardarsson, Clive P. Page, Fredrik Lehmann, Thorarinn Gudjonsson. “Barriolides: Nonantibacterial compounds with epithelial barrier enhancing properties and anti-inflammatory effects in vitro.” Abstract submitted to 15th World Congress on Inflammation, 5–8 June, 2022, Rome, Italy. Jennifer A. Kricker, Sævar Ingthorsson, Michael J. Parnham, Bryndís Valdimarsdóttir, Jon Petur Joelsson, Snævar Sigurdsson, Fridrik R. Gardarsson, Clive P. Page, Ólafur Baldursson, Fredrik Lehmann, Thorarinn Gudjonsson. “Targeting the lung epithelial barrier to inhibit neutrophilic inflammation.” https://doi.org/10.1124/pharmrev.121.000300 Publisher Copyright: © 2021 by The Author(s). Macrolides are among the most widely prescribed broad spectrum antibacterials, particularly for respiratory infections. It is now recognized that these drugs, in particular azithromycin, also exert time-dependent immunomodulatory actions that contribute to their therapeutic benefit in both infectious and other chronic inflammatory diseases. Their increased chronic use in airway inflammation and, more recently, of azithromycin in COVID-19, how-ever, has led to a rise in bacterial resistance. An addi-tional crucial aspect of chronic airway inflammation, such as chronic obstructive pulmonary disease, as well as other inflammatory disorders, is the loss of ...